Dr. David J. Kwiatkowski is a thoracic oncologist and genetic researcher with expertise in all types of thoracic malignancies. His particular interests include therapeutic targeting and personalized medicine approaches to cancer patient care. He is also a visiting scientist at the Broad Institute, where he is engaged in many cancer genome sequencing projects, including The Cancer
Dr. Pasi A. Jänne is a leading researcher and clinician in medical oncology and lung cancer. He was one of the co-discoverers of epidermal growth factor receptor (EGFR) mutations. He has played an integral role in the development of targeted therapeutic strategies for patients with those mutations, as well as in the identification of molecular
Two of America’s most highly respected mesothelioma professionals have been named to new positions at the prestigious International Mesothelioma Interest Group (iMig). Joseph Friedberg, MD, FACS, and Melissa Culligan, RN, BSN, MSc, PhD candidate will bring the expertise that they deploy at Temple Health, the Lewis Katz School of Medicine at Temple University, and Fox
Dr. Bruce E. Johnson is a world-renowned lung cancer physician-scientist. As leader of the Lung Cancer Program for the Dana-Farber/Harvard Cancer Center in Boston, he oversees research that integrates the facilities’ patient populations and science and applies what is discovered to the treatment of patients with lung cancer, mesothelioma, and other thoracic malignancies. Education and
Dr. Hassan A. Khalil is a thoracic surgeon at Brigham and Women’s Hospital and Dana-Farber Cancer Institute. He specializes in minimally invasive surgical techniques in the treatment of thoracic and foregut diseases, including pleural mesothelioma and lung cancer. He is a certified robotic console surgeon in the da Vinci Xi robotic platform and is also skilled
Dr. David M. Jackman is a thoracic oncologist who is dedicated to improving outcomes for patients diagnosed with lung cancer, pleural mesothelioma, and thymic tumors at the Dana-Farber Cancer Institute. As a physician member of the Lowe Center for Thoracic Oncology, he collaborates with experts across medical disciplines to coordinate and create a plan of
Dr. Petr F. Hausner is a medical oncologist at the University of Maryland Medical Center and the Greenebaum Comprehensive Cancer Center. His clinical specialties are hematology and oncology, thoracic oncology, gastrointestinal oncology, and cutaneous oncology. Working with a multidisciplinary team, he designs treatment plans for patients diagnosed with lung cancer, pleural mesothelioma, and peritoneal mesothelioma,
Dr. Katherine A. Scilla is a medical oncologist at the University of Maryland Medical Center and part of the Greenebaum Comprehensive Cancer Center’s Mesothelioma and Thoracic Oncology Treatment and Research Center Team. She specializes in treating chest and thoracic cancers, including malignant pleural mesothelioma, lung cancer, and thymic cancers. Education and Career Dr. Scilla attended
Mesothelioma is a particularly challenging form of cancer that has proven extremely resistant to traditional treatment protocols. Most patients are offered multimodality treatments that include chemotherapy, and that regimen can lead to a troubling side effect referred to as ‘chemobrain.’ This week researchers have published a study that suggests that it may be caused by
Dr. Jordan D. Miller is a thoracic surgeon and member of the Lung and Thoracic Cancer Team at the University of Kentucky’s UK Markey Cancer Center. He specializes in treating patients with lung cancer, esophageal cancer, pleural mesothelioma, and other conditions, using a variety of high-level techniques, including minimally invasive surgery and video-assisted thoracoscopic surgery.